微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 14.72% | 40.51% | -4.19% | 141/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 15.36% | 27.56% | 9.61% | 145/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 14.01% | 5.97% | -6.78% | 144/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 15.03% | 25.57% | 43.52% | 144/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 10.47% | -11.45% | -13.02% | 143/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 12.04% | 53% | -8.94% | 145/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 13.22% | 84.11% | 10.46% | 143/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 11.97% | 88.44% | 1.21% | 143/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 11.83% | 42.56% | 50.3% | 140/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 7.87% | -66.13% | 9.57% | 147/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 7.18% | -65.86% | 13.06% | 139/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 6.35% | -72.04% | -23.43% | 143/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 8.3% | -73.82% | -64.29% | 133/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 23.23% | -38.3% | 10.44% | 139/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 21.04% | -46.94% | -7.39% | 127/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 22.72% | -44.75% | -28.31% | 134/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 31.69% | -5.34% | -15.86% | 102/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 37.66% | 343.62% | -5.01% | 111/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 39.65% | 1954.4% | -3.57% | 90/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 41.12% | 1524.58% | 22.82% | 93/158 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 33.48% | 779.22% | 779.22% | 94/158 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-03-31 | 3.81% | 597.07% | 124.63% | 105/158 | 51.05% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | -15.46% | -3.5% | -623.01% | 131/158 | -208.09% | 微芯生物 | 96.09% | 行业排名> |
| 2017-09-30 | -2.14% | 88.42% | 25.92% | 97/158 | 49% | 微芯生物 | 96.11% | 行业排名> |
| 2017-06-30 | -2.89% | 83.41% | -628.41% | 103/158 | 47.74% | 微芯生物 | 95.5% | 行业排名> |
| 2017-03-31 | 0.55% | 106.59% | 103.66% | 88/158 | 46.55% | 微芯生物 | 96.27% | 行业排名> |
| 2016-12-31 | -14.94% | -2790.61% | 19.11% | 112/158 | 48.19% | 贝达药业 | 95.47% | 行业排名> |
| 2016-09-30 | -18.46% | -1379.31% | -6.11% | 81/158 | 45.76% | 贝达药业 | 95.51% | 行业排名> |
| 2016-06-30 | -17.4% | -2030.44% | -109.8% | 90/158 | 45.89% | 贝达药业 | 95.54% | 行业排名> |
| 2016-03-31 | -8.29% | -249.64% | -1505.17% | 80/158 | 43.5% | 贝达药业 | 95.74% | 行业排名> |
| 2015-12-31 | -0.52% | 98.57% | 58.6% | 103/158 | 45.97% | 退市金泰 | 96.19% | 行业排名> |
| 2015-09-30 | -1.25% | 96.41% | -238.47% | 78/158 | 44.69% | 贝达药业 | 95.81% | 行业排名> |
| 2015-06-30 | 0.9% | 103.28% | 138% | 82/158 | 45% | 退市金泰 | 95.93% | 行业排名> |
| 2015-03-31 | -2.37% | 79.62% | 93.43% | 76/158 | 43.46% | 贝达药业 | 95.58% | 行业排名> |